glp-1 drug delivery devices FDA Approves First Generic Liraglutide for Weight Loss Advances in GLP-1 receptor agonists

What began as a strategy for controlling blood sugar has evolved into a window into deeply integrated physiological networks

Average weight loss is 5-7% of body weight

But weight loss is crucial for many osteoarthritis patients, and these medications offer a huge opportunity to instigate successful change

doi: 10.1371/journal.pone.0228685

FlexTouch and KwikPen delivery systems minimize injection errors critical for GLP-1 therapies where dose escalation spanning 16 to 20 weeks requires milligram-level titration

Molecular cloning of the rat intestinal proglucagon cDNA similarly revealed an open reading frame identical to that elucidated for the rat pancreatic islet proglucagon cDNA (52)